influenza
virus
iv
respons
signific
morbid
mortal
human
popul
annual
death
worldwid
iv
caus
sever
acut
respiratori
diseas
especi
highrisk
popul
like
children
elderli
immunocompromis
influenza
b
virus
iav
ibv
respect
caus
annual
epidem
major
sever
human
infect
caus
iav
iv
segment
negativesens
singlestrand
rna
genom
lack
proofread
activ
viral
rnadepend
rna
polymeras
rdrp
success
replic
lead
accumul
nucleotid
mutat
drive
antigen
drift
addit
segment
natur
genom
allow
genet
reassort
iv
take
place
produc
novel
strain
acquir
altern
antigen
distinct
hemagglutinin
also
known
antigen
shift
antigen
drift
antigen
shift
contribut
iv
abil
evad
preexist
host
immun
induc
previou
infect
earli
recognit
respons
iv
infect
larg
mediat
innat
immun
sensor
express
primari
target
alveolar
epitheli
cell
recognit
iv
mediat
pattern
recognit
receptor
prr
includ
toll
like
receptor
tlr
retinoinc
acid
induc
genei
rigi
nucleotid
oligomer
domain
nod
like
receptor
famili
pyrin
domain
contain
recogn
viral
rna
variou
stage
infect
cycl
activ
sensor
trigger
signal
cascad
lead
product
interferon
well
proinflammatori
cytokin
chemokin
ultim
result
antivir
state
within
surround
cellstissu
accordingli
iv
multipl
mechan
evad
respons
mediat
viral
nonstructur
protein
polymeras
basic
protein
polymeras
basic
protein
polymeras
acid
pa
nucleoprotein
np
review
van
de
sandt
et
al
chen
et
al
otherwis
healthi
individu
iav
infect
mild
ensu
pro
antiinflammatori
respons
balanc
contrast
cytokin
storm
typic
associ
sever
infect
includ
caus
highli
pathogen
iv
strain
cytokin
storm
chemokin
cytokin
respons
dysregul
intens
kinet
result
excess
damag
host
due
infiltr
inflammatori
immun
cell
acut
lung
injuri
ali
caus
inflammatori
respons
typic
character
signific
damag
destruct
respiratori
epithelium
lead
acut
respiratori
distress
syndrom
ard
clinic
treatment
option
sever
influenza
viru
infect
remain
limit
reli
heavili
administr
antivir
neuraminidas
inhibitor
nai
support
critic
care
howev
nai
effect
patient
sever
infect
evid
fatal
outcom
associ
develop
antivir
resist
patient
virustarget
therapi
remain
standard
approach
iv
mutabl
adapt
current
antivir
highlight
need
new
therapeut
option
target
host
factor
regul
iv
infect
result
immun
respons
either
approach
focu
prevent
limit
damag
lung
epithelium
due
exagger
dysregul
immun
cell
respons
biolog
respons
modifi
brm
alter
immun
respons
therebi
offer
addit
therapeut
approach
treat
sever
infect
review
highlight
sever
studi
shown
viabil
brm
potenti
treatment
option
clariti
brm
categor
base
type
biolog
agent
tabl
iav
infect
vaccin
elicit
broadlyneutr
antibodi
ab
target
viral
hastem
howev
abund
immunesubdomin
overshadow
ab
target
hahead
domain
effect
hastem
ab
broad
rang
iav
subtyp
make
attract
target
vaccin
develop
also
antivir
inde
sever
hastem
specif
human
monoclon
ab
evalu
clinic
trial
review
davidson
human
monoclon
ab
shown
control
viral
replic
improv
symptom
human
patient
phase
clinic
trial
virusspecif
ab
aim
reduc
antigen
load
ab
host
target
aim
limit
secondari
wave
cytokin
reduc
prolong
damag
cellular
infiltr
sever
infect
hosttarget
direct
antibodi
util
target
key
regul
inflammatori
wave
could
potenti
use
dampen
overt
respons
angiopoietinlik
solubl
angiogenicregul
protein
follow
proteolyt
cleavag
ctermin
portion
involv
integrindepend
wound
repair
regul
vascular
permeabl
significantli
elev
lung
biopsi
iavinduc
pneumonia
patient
mous
studi
neutral
ab
reduc
pulmonari
tissu
leaki
significantli
acceler
lung
recoveri
improv
lung
tissu
integr
neutrophil
infiltr
alveolar
space
occur
within
day
follow
iav
infect
neutrophil
extracellular
trap
net
releas
iavinduc
pneumonia
alveolar
space
caus
alveolar
damag
complement
protein
shown
induc
net
releas
administr
ab
reduc
ali
due
reduc
infiltr
lung
macrophag
neutrophil
well
reduct
viral
load
african
green
monkey
tumor
necrosi
factor
alpha
key
cytokin
control
sever
iav
infect
regul
two
main
antivir
function
induct
nfkb
pathway
ultim
control
express
sever
inflammatori
cytokin
ii
apoptosi
multipl
signal
cascad
tnf
upregul
iav
infect
correl
infect
sever
especi
follow
highli
pathogen
iavinfect
mice
treat
antitnf
ab
show
reduc
diseas
burden
howev
author
studi
report
effect
viral
replic
tnfrelat
apoptosi
induc
ligand
trail
trigger
apoptosi
iavinfect
cell
iavinfect
human
epitheli
cell
sensit
trailmedi
apoptosi
peripher
blood
mononuclear
cell
upregul
trail
express
moreov
administr
monoclon
ab
trail
increas
surviv
rate
follow
iav
infect
mous
studi
antimicrobi
peptid
amp
host
protein
direct
antibacteri
antivir
activ
modul
immun
respons
infect
literatur
larg
focus
antibacteri
aspect
amp
sever
studi
highlight
antivir
potenti
amp
sever
virus
includ
iv
review
hsieh
hartshorn
albericio
kruger
human
cathelicidin
deriv
amp
found
predominantli
neutrophil
express
also
induc
epitheli
cell
macrophag
aerosol
administr
either
human
mous
counterpart
mcramp
led
reduc
morbid
mortal
similar
level
neuraminidas
inhibitor
zanamivir
use
treatment
human
influenza
patient
cellular
viral
faddlik
enzymeinhibitori
protein
cflip
vflip
respect
protect
cell
death
receptor
mediat
apoptosi
vflipderiv
peptid
consist
amino
acid
helix
kaposi
sarcoma
herp
viru
kshv
death
effector
domain
protein
synthet
version
peptid
gener
fuse
portion
hiv
tat
protein
mous
challeng
studi
intranas
administr
time
infect
highli
pathogen
avian
viru
result
protect
treat
mice
replic
viru
detect
lung
either
day
infect
suggest
complet
protect
infect
note
effect
larg
due
direct
destabil
virion
peptid
like
infect
treat
mice
establish
efficaci
amp
determin
establish
infect
warrant
investig
host
kinas
regul
iav
entri
replic
also
initi
antivir
signal
cascad
regul
express
proinflammatori
chemokin
cytokin
infect
present
viabl
target
intervent
iav
infect
shown
upregul
cjun
ntermin
kinas
kinas
directli
regul
induct
proinflammatori
respons
iavinduc
activ
mediat
product
chemokin
cytokin
includ
interferon
interleukin
vivo
inhibit
result
reduc
level
proinflammatori
cytokin
reduc
viral
titer
mitogen
activ
protein
kinas
mapk
regul
viral
entri
replic
furthermor
regul
ifn
stimul
gene
isg
gene
express
ultim
cytokin
product
via
phosphoryl
use
either
two
specif
inhibitor
sb
sb
mice
protect
lethal
infect
exhibit
reduc
mortal
proinflammatori
respons
activ
anoth
mapk
mek
requir
effici
iav
replic
inhibit
result
viral
ribonucleoprotein
vrnp
retent
reduc
titer
progeni
viru
importantli
treatment
mice
clinic
approv
mek
inhibitor
show
reduc
lung
viral
load
mortal
mice
follow
infect
lethal
dose
pandem
iav
interestingli
inhibitor
significantli
outperform
clinic
recommend
oseltamivir
studi
anoth
central
regul
immun
respons
epithelium
well
immun
cell
signal
pathway
accordingli
iav
evolv
sever
mechan
modul
pathway
counteract
antivir
respons
includ
directli
target
ikb
kinas
ikk
potent
nfkb
inhibitor
function
reduc
abil
subunit
nfkb
complex
bind
dna
therebi
limit
transcriptionregul
function
vivo
administr
day
lethal
infect
either
avian
virus
result
signific
protect
mice
surviv
show
littl
clinic
symptom
similar
result
obtain
prophylact
administr
gprotein
coupl
receptor
kinas
best
known
phosphoryl
gpcr
cardiac
tissu
result
recruit
facilit
rapid
receptor
intern
lysozom
degrad
recent
phosphoproteom
studi
identifi
potenti
provir
host
protein
iav
play
major
role
virion
uncoat
although
vivo
inhibit
use
paroxetin
led
signific
reduct
upper
respiratori
tract
viral
load
modest
reduct
lower
respiratori
tract
titer
day
post
infect
inhibit
protect
lethal
infect
howev
possibl
rout
administr
intraperiton
vs
intranas
dose
regimen
influenc
result
sphingosin
kinas
sphk
lipid
kinas
mediat
convers
sphingosin
bioactiv
lipid
sphingosin
known
modul
central
apoptot
pathway
iav
infect
lead
increas
express
activ
vitro
inhibit
shown
decreas
iav
rna
synthesi
via
suppress
nfkb
activ
treatment
mice
specif
inhibitor
either
pansphk
inhibitor
led
prolong
surviv
mice
follow
lethal
iav
infect
peroxisom
proliferatoractiv
receptor
regul
metabol
homeostasi
import
mediat
inflammatori
respons
sever
ppar
agonist
investig
efficaci
iav
infect
vari
result
gemfibrozil
agonist
improv
symptom
administ
day
infect
viru
also
increas
surviv
iav
infect
mice
prophylact
treatment
mice
pioglitazon
agonist
result
increas
surviv
combin
activ
downstream
target
ampk
improv
surviv
mice
infect
pandem
iav
strain
proteas
activ
receptor
par
link
proteas
activ
inflammatori
cellular
respons
express
upregul
mous
airway
follow
iav
infect
intranas
administr
antagonist
time
infect
variou
iav
strain
includ
highli
pathogen
avian
pandem
virus
led
increas
surviv
decreas
inflammatori
respons
moreov
effect
also
observ
administ
h
infect
use
statin
angiotensin
ii
receptor
blocker
arb
angiotensin
convert
enzym
inhibitor
acei
propos
regul
iavinduc
cytokin
storm
sever
infect
retrospect
studi
conduct
separ
mexico
netherland
uk
usa
report
associ
reduc
iavrel
pneumonia
lower
case
fatal
due
lower
respiratori
tract
iav
infect
statin
treatment
howev
associ
contest
two
addit
studi
found
benefit
statin
treatment
iavinduc
diseas
burden
uncertainti
regard
iav
therapeut
potenti
wide
use
compound
warrant
investig
basic
scienc
level
clinic
trial
continu
accumul
adapt
mutat
introduct
novel
virus
human
popul
continu
pose
threat
public
health
especi
individu
high
risk
influenza
emerg
strain
resist
exist
class
antivir
drug
reduc
vaccin
effect
highlight
need
develop
altern
intervent
strategi
therefor
therapeut
approach
diminish
potenti
drugresist
effect
multipl
iav
subtypesstrain
highli
desir
target
host
cell
factor
meet
criteria
like
avoid
overtli
robust
immun
respons
therebi
reduc
diseas
sever
improv
patient
outcom
figur
larg
effort
made
recent
year
identifi
host
protein
serv
intervent
target
iv
infect
sever
genet
proteom
screen
identifi
sever
promis
hit
potenti
role
iv
replic
cycl
addit
genomewid
screen
viral
host
protein
interact
map
network
also
use
identifi
host
factor
critic
iv
replic
interestingli
metaanalysi
studi
show
limit
overlap
genesprotein
identifi
requir
host
factor
like
due
studyspecif
variat
iv
typesstrain
celllin
use
inclusionexclus
criteria
limit
hitvalid
method
use
knockdownout
gene
local
microenviron
within
given
tissu
dictat
qualiti
intens
immun
respons
inhibit
activ
critic
signal
pathway
express
respiratori
tract
epitheli
immun
cell
brm
opposit
unintend
consequ
discuss
trail
regul
immun
cellmedi
apoptosi
infect
cell
sever
studi
shown
block
trail
signal
genom
delet
deplet
monoclon
antibodi
administr
improv
infect
outcom
iavinfect
mice
inde
inhibit
trail
signal
alveolar
macrophag
monocyt
limit
abil
induc
apoptosi
alveolar
cell
prevent
lung
tissu
damag
promot
surviv
howev
cell
mice
less
abl
protect
mice
sever
infect
consist
impair
trailmedi
effector
function
cell
similarli
oppos
benefici
detriment
outcom
also
observ
studi
use
inhibitor
treat
iav
infect
brm
deliveri
guid
immun
system
compartment
ensur
elicit
balanc
immun
respons
ideal
mucos
deliveri
deposit
brm
reduc
viral
titer
site
iav
replic
howev
system
deliveri
certain
brm
might
requir
dampen
dysregul
respons
depend
brm
use
also
time
administr
moreov
durat
treatment
brm
must
consid
sustain
inhibit
certain
inflammatori
respons
result
immun
statu
increas
suscept
secondari
opportunist
infect
repurpos
clinic
approv
drug
could
potenti
use
brm
treatment
sever
iav
infecti
explor
consid
suscept
sever
iav
infect
influenc
host
genet
hostspecif
immun
respons
select
therapeut
brm
carri
use
vivo
model
system
repres
immun
statu
spectrum
underli
condit
highrisk
influenza
patient
young
immunocompromis
nonnaiv
obes
pregnant
age
use
model
system
increas
likelihood
identifi
brm
clinic
relev
antivir
immunomodulatori
potenti
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
